Publikationen in Zusammenarbeit mit Forschern von Weill Cornell Medical College in Qatar (11)

2023

  1. Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management

    International Journal of Dermatology, Vol. 62, Núm. 8, pp. 1020-1025

  2. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10411, pp. 1423-1433

2019

  1. Nonmelanoma skin cancer in childhood and young adult cancer survivors previously treated with radiotherapy

    JNCCN Journal of the National Comprehensive Cancer Network, Vol. 17, Núm. 3, pp. 237-243

  2. Treatment outcomes of immune-related cutaneous adverse events

    Journal of Clinical Oncology, Vol. 37, Núm. 30, pp. 2746-2758

2015

  1. Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies[ Breast Cancer Res Treat (2014), 148, 553-561, DOI 10.1007/s10549-014-3144-y]

    Breast Cancer Research and Treatment

  2. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

    Science Translational Medicine, Vol. 7, Núm. 283

2014

  1. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

    Breast Cancer Research and Treatment, Vol. 148, Núm. 3, pp. 553-561

  2. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer

    Oncologist, Vol. 19, Núm. 4, pp. 318-327

2013

  1. Dasatinib plus capecitabine for advanced breast cancer: Safety and efficacy in phase I study CA180004

    Clinical Cancer Research, Vol. 19, Núm. 7, pp. 1884-1893

2011

  1. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study

    The Lancet, Vol. 377, Núm. 9769, pp. 914-923

2010

  1. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

    Clinical Breast Cancer